Sm_mary There is a well-known raised risk of leukaemia in children with neurofibromatosis type 1 (NF-1).
Leukaemia in a child with neurofibromatosis type 1 (NF-1) was first reported more than 30 years ago (Royer et al., 1958) . Since then there have been numerous other case reports. The largest series to date was that of Bader and Miller (1978) , who ascertained 12 children with leukaemia and NF-1 from a group of 16 university hospitals and a multicentre childhood cancer survey in the USA; to these they added 17 previously published cases occurring below age 20. Their study was not population based but, as the total number of cases of leukaemia from only 16 hospitals was similar to that expected nationally on the basis of incidence data, it seemed likely that children with NF-I had an overall increased risk of leukaemia and there was an especially marked excess of juvenile chronic myeloid leukaemia (JCML). In a recent investigation of the heritable fraction of childhood cancer in Britain using data from the populationbased National Registry of Childhood Tumours, the estimated relative risk of leukaemia in children with NF-1 was 3.8 overall, with a 70-fold excess of chronic myeloid leukaemia (CML) and a relative risk of 2.7 for acute lymphoblastic leukaemia (ALL) (Narod et al., 1991) .
The present report concerns the first detailed populationbased study of leukaemia and non-Hodgkin lymphoma (NHL) associated with NF-1. The purpose of this study was to estimate the risk of leukaemia and NHL in children with NF-I and to elucidate the relationship between these conditions in greater detail and on the basis of larger numbers of cases than in the previous study.
Patients and methods
The National Registry of Childhood Tumours (NRCT) includes information on children who were domiciled in England, Scotland or Wales and aged under 15 at the time of diagnosis with a malignant neoplasm. The principal sources of ascertainment are the National Cancer Registration Schemes, which cover the whole of Britain through a network of regional registries, the register of children under the care of members of the United Kingdom Children's Cancer Study Group (UKCCSG), local population-based childhood cancer registries in several regions, death certificates and entries to the Medical Research Council leukaemia trials. It has recently been estimated that, from all these sources combined, the NRCT ascertained 99.5% of all children in Britain with leukaemia or non-Hodgkin lymphoma (NHL) diagnosed during 1974-83 . During 1981-84, over three-quarters of children in Britain with these diagnoses were registered with UKCCSG (Stiller, 1988) (Chessells, 1991) , but we attempted to assign a morphological diagnosis on the basis of the French-American-British (FAB) classification (Bennett et al., 1982) .
For both diagnostic groups, reports of cytogenetic studies were obtained for review in cases where these had been done.
Relative risks were calculated by dividing the observed numbers of cases of NF-I among patients with each type of leukaemia or lymphoma by the expected number, assuming the childhood population prevalence of NF-I of 1:2,558, which was estimated by Huson et al. (1989) (Bader & Milkr, 1978; Narod et al., 1991) . From (Sieff et al., 1981) . NE-l has been described both in patients with this infantile monosomy 7 syndrome and in others with myelodysplasia who develop monosomy 7 with evolution of their disease (Kaneko et al., 1989; Shannon et al., 1992 in association with NF-1 (McEvoy & Mann, 1971; Bader & Miller, 1978) in fact had infantile monosomy 7. A previous study suggested that astrocytomas occurring in people with NF-1 may be unusually aggressive (Ilgren et al., 1985) , but there is no obvious indication from the present series that leukaemia or NHL associated with NF-1 has a particularly poor prognosis.
The increased risk of leukaemia in NF-1 is enigmatic because it is one of the few malignancies associated with NF-I that does not primarily involve cells derived from the neural crest. Bader and Miller (1978) suggested that the association might be elucidated by further study of the clonal status of leukaemias in NF-1 and a search for chromosomal abnormalities. Shannon et al. (1994) have recently demonstrated loss of heterozygosity of the NFI allele in the bone marrow of five out of nine children with NF-I and myelodysplasia or ANLL, indicating that NFI acts as a tumour suppressor in myeloid cells. Cytogenetic studies were available for review in a disappointingly low proportion of patients in the present study, though this is partly a reflection of the length of time since the earliest cases were diagnosed, and with improvements in cytogenetic methodology much better information would be expected from a prospective study. The only specific clonal abnormality reported in a child with ALL involved deletion of 17p, on which the p53 tumour-suppressor gene is located. Deletions of 17p have previously been found in neurofibrosarcomas associated with NF-l (Menon et al., 1990) .
The predominance of familial NF-1 in children with JCML and higher proportion of apparently sporadic NF-1 in those with ALL agree with the findings of Bader and Miller (1978) . In a review of children with NF-I and myeloproliferative disease, Shannon et al. (1992) found that inheritance of NF-1 was maternal in 16 (76%) and paternal in five (24%) of 21 cases: for JCML alone the proportions were 12/17 (71%) maternal and 5/17 (29%) paternal. In our series the proportion with maternal inheritance of NF-1 was substantially lower, and the most recent series of Shannon et al. (1994) contained roughly equal numbers of children with maternal and paternal inheritance.
There has been one previous report of three cases of T-cell NHL occurring with NF-I in a single sibship (Kaplan et al., 1982) , but that family differed in several respects from the one reported here: there was no evidence of consanguinity in the parents; none of the affected patients developed a second malignant neoplasm, but the maximum survival time from diagnosis of NHL was only 8 months; one of the three sibs also had features of familial polyposis coli. Pratt et al. (1988) reported two other families in which NHL occurred in conjunction with NF-I and polyposis coli; both were found to have consanguinity, though in one the common ancestor was five generations earlier. Immunophenotype of the lymphomas was not reported, but one was mediastinal, and thus probably T cell. It seems likely that the family of cases 17-19 in the present series is affected by the same syndrome, though polyposis coli has not yet been detected.
In conclusion, the association of inherited NF-1 with myeloproliferative disease in boys suggests a multistep process of leukaemogenesis (Shannon et al., 1992) . The recent results of Shannon et al. (1994) indicate that the NFl allele acts as a tumour suppressor in myeloid cells, though several of their cases showed no loss of heterozygosity. Further elucidation of this point may be provided by a prospective study of cases of this extremely rare combination of diseases which will be facilitated by the national childhood myelodysplasia registry. There is so far no evidence that abnormalities of the NFl gene account for the raised risk of lymphoid malignancy in NF-1, but one of our patients had a deletion of 17p, including the p53 tumour-suppressor gene. We intend to review any future cases of leukaemia or NHL in children with NF-1 in order to detect possible cytogenetic abnormalities.
